## ZTS: Zoetis Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 2.21 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($115.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Elanco Animal Health (NYSE:ELAN) Price Target Raised to $22.00**
- Source: MarketBeat | 20251218T180848 | Somewhat-Bullish | Relevance: 62%
- Morgan Stanley raised its price target on Elanco Animal Health (NYSE:ELAN) to $22.00, maintaining an "equal weight" rating, following strong Q3 results. Other analysts also show bullish sentiment with a consensus "Moderate Buy" rating and a mean target of $23.78. Notable insider buying by CEO Jeffrey Simmons and other insiders further highlights confidence in the company, which reported strong quarterly earnings and positive FY2025 guidance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $136 | $0 | 0% |
| 2025-12-03 | BTIG | $160 | $160 | 0% |
| 2025-11-21 | Keybanc | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |
| 2025-12-03 | BTIG | reit | Buy |
| 2025-11-21 | Keybanc | init | Sector Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 8 ($0.32M) |
| Sells | 1 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+1.0%)
- Blackrock Inc.: 8.2% (-2.8%)
- State Street Corpora: 4.5% (-0.5%)
- Morgan Stanley: 3.8% (-4.3%)
- State Farm Mutual Au: 3.6% (0.0%)

### Key Risks

1. Long-term trend broken: trading 17.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.21 elevated, pricing in significant growth expectations. Forward P/E 18.0x stretched relative to 7% growth. Quality metrics strong (ROE 50%, ROA 15%, margin 28%). Balance sheet: strong liquidity (3.6x). Institutional flow bearish (7 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $54.2B |
| Beta | 0.97 |
| 52W Range | $115.25 - $177.40 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.21 |
| Forward P/E | 18.0 |
| Current P/E | 19.3 |
| YoY Growth | 6.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.2% (minimal 5-day change). Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Below SMA200 (0.82x), long-term trend not supportive. MACD histogram positive (0.91), confirming momentum. RSI neutral at 47. Elevated volume (1.4x 20MA), institutional activity likely. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.24% (CS: 48) | Neutral |
| RSI_14 | 47.3 | Neutral |
| MACD Histogram | 0.91 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 0.947x | Below |
| vs SMA200 | 0.821x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $122.22
- **Stop Loss:** $115.78 (5.3% risk)
- **Target:** $128.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 186
- **Position Value:** $22,732.92
- **Portfolio %:** 22.73%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.62 | $1.70 | +4.8% |
| 2025Q2 | $1.61 | $1.76 | +9.2% |
| 2025Q1 | $1.40 | $1.48 | +5.8% |
| 2024Q4 | $1.36 | $1.40 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*